Oxford Cannabinoid Tech.Holdings New Broker and Investor Presentation (5218L)

TIDMOCTP

RNS Number : 5218L

Oxford Cannabinoid Tech.Holdings

16 May 2022

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or "the Company")

Appointment of Axis Capital Markets as Corporate Broker

Notice of Investor Meet Company Live Q&A Session

Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market, is pleased to announce the appointment of Axis Capital Markets Limited ("AxCap") as the Company's corporate broker with immediate effect ( www.axcap247.com ).

AxCap will work alongside OCTP's existing financial adviser, Cairn Financial Advisers LLP.

Investor Meet Company Q&A Session, 4:30 p.m., 30 May 2022

The Company is also pleased to announce that it will be hosting a live online Q&A session via the Investor Meet Company platform at 4:30 p.m. BST on 30 May 2022, which is open to all existing and potential shareholders.

Questions can be submitted pre-event via the 'Investor Meet Company' dashboard up until 9:00 a.m. on Friday 27 May 2022 or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor

Investors who already follow OCTP on the Investor Meet Company platform will automatically receive an invitation to the event. The Company will also use this opportunity to respond to questions already received.

The Directors of the Company accept responsibility for the content of this announcement.

Enquiries:

 
 Oxford Cannabinoid Technologies        +44 (0)20 3034 2820 
  Holdings plc                           john@oxcantech.com 
  Dr John Lucas (CEO)                    clarissa@oxcantech.com 
  Clarissa Sowemimo-Coker (COO) 
 Cairn Financial Advisers LLP 
  Emily Staples                           +44 (0)20 7213 0897 
  Jo Turner                               +44 (0)20 7213 0885 
 Axis Capital Markets Limited           +44 (0)20 3026 0320 
  Kamran Hussain 
  Richard Hutchison 
 
  Walbrook PR Limited                    +44 (0)20 7933 8780 
  Paul Vann/Nick Rome                    +44 (0)7768 807631 
                                         oxcantech@walbrookpr.com 
 
  Harbor Access LLC 
  Richard Leighton/Jonathan Paterson     +1 (475) 455 9403 
                                         Richard.Leighton@HarborAccessllc.com

About Oxford Cannabinoid Technologies Holdings plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market (together the "Group"). Cannabinoids are compounds found in the cannabis plant that have been shown to have a range of therapeutic effects on the body, including pain relief. The Group has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities. The Group's lead compound, OCT461201, is a highly potent and selective CB2 agonist and is being developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical testing and development with clinical trials scheduled for Q1 2023. The Group's product pipeline also uses a balanced drug product strategy that employs both natural and synthetic compounds for the treatment of rare diseases and includes chemically modified phytocannabinoids with improved drug-like characteristics and a proprietary library of cannabinoids.

OCTP operates a partnership model with external academic and commercial partners.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFVDEAIVLIF

(END) Dow Jones Newswires

May 16, 2022 02:01 ET (06:01 GMT)

Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Aug 2024 to Sep 2024